CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to TCI Co., Ltd BioCosme PABP BRANCH, 2026-09-02
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
At a glance: The FDA Center for Drug Evaluation and Research issued a warning letter (Reference 320-26-122, dated September 2, 2026) to TCI Co., Ltd BioCosme PABP BRANCH regarding significant Current Good Manufacturing Practice (CGMP) violations at its facility in Pingtung County, Taiwan (FEI 3014217121), identified during an inspection from March 9–13, 2026. The letter cites two primary violations: failure to perform appropriate laboratory testing (including assay testing of active pharmaceutical ingredients) on finished OTC drug product batches before release to the U.S. market, and failure to adequately test incoming components for identity and conformity with specifications while validating supplier test results at appropriate intervals. The FDA states the firm's response to its Form FDA 483 was inadequate and requires the firm to provide a comprehensive quality agreement defining testing and release responsibilities and a list of chemical and microbial test methods and specifications used for lot disposition decisions.
Argus analysis
# FDA Warning Letter Analysis: TCI Co., Ltd BioCosme PABP BRANCH
**Company and Violations**
TCI Co., Ltd BioCosme PABP BRANCH, a contract pharmaceutical manufacturer headquartered in Taipei, Taiwan, received a Warning Letter from the FDA's Center for Drug Evaluation and Research (CDER) on September 2, 2026, following an inspection conducted March 9–13, 2026. The FDA identified significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished over-the-counter drugs. The agency determined that drug products manufactured at the facility were adulterated because methods, facilities, and controls failed to meet federal standards.
**Regulatory Citations and Their Significance**
The violations centered on 21 CFR parts 210 and 211, which establish mandatory CGMP requirements for drug manufacturers. Specifically, the FDA cited 21 CFR 211.165(a), which requires laboratories to determine that each drug batch conforms to final specifications before release, and 21 CFR 211.84(d)(1) and (d)(2), which mandate component identity and purity testing with validation of supplier test results at appropriate intervals. The violations indicated that TCI released finished products to the U.S. market without performing assay testing of active pharmaceutical ingredients and failed to verify incoming raw materials against United States Pharmacopeia monographs, including critical identity and heavy metals testing.
**Timeline and Industry Monitoring**
TCI submitted a response to the FDA's Form FDA 483 on April 2, 2026, which the agency deemed inadequate due to insufficient supporting documentation and corrective action evidence. The Warning Letter requires TCI to provide written quality agreements with customers, comprehensive component testing procedures, and supplier validation protocols. Compliance officers in contract manufacturing should monitor whether TCI submits adequate corrective action documentation and whether the FDA initiates enforcement action such as import detention or product recalls.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER TCI Co., Ltd BioCosme PABP BRANCH MARCS-CMS 736888 — September 02, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Reference #: 320-26-122 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Vincent Lin Recipient Title Chief Executive Officer TCI Co., Ltd BioCosme PABP BRANCH 8F, No. 187, Gangqian Rd. Neihu District , Taipei City 11494 Taiwan vincent@tci-bio.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States September 2, 2026 WARNING LETTER Reference number: 320-26-122 To Vincent Lin: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice. FDA Inspection Violations were identified and documented during an inspection of your drug manufacturing facility, TCI Co., Ltd. - BioCosme PABP BRANCH, FDA Establishment Identifier (FEI) 3014217121, at No. 21 Nongke Rd., Changzhi Township, Pingtung County, Taiwan, from March 9 to March 13, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your April 2, 2026, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility. 1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to …
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was TCI Co., Ltd BioCosme PABP BRANCH cited for?
- The FDA Warning Letter to TCI Co., Ltd BioCosme PABP BRANCH (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to TCI Co., Ltd BioCosme PABP BRANCH?
- FDA issued the letter (MARCS-CMS 736888) on 2026-09-02 and posted it publicly on fda.gov on 2026-10-06.
- Is the FDA warning letter to TCI Co., Ltd BioCosme PABP BRANCH publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tci-co-ltd-biocosme-pabp-branch-736888-09022026.
- What does a "high" severity rating mean for this letter?
- High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to TCI Co., Ltd BioCosme PABP BRANCH, 2026-09-02. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-tci-co-ltd-biocosme-pabp-branch-2026-09-02-cgmp
"CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to TCI Co., Ltd BioCosme PABP BRANCH, 2026-09-02." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-tci-co-ltd-biocosme-pabp-branch-2026-09-02-cgmp.
Argus HQ Research. "CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to TCI Co., Ltd BioCosme PABP BRANCH, 2026-09-02." Digital Empire Holdings LLC. Accessed October 7, 2026. https://argushq.ai/fda/warning-letter/fda-wl-tci-co-ltd-biocosme-pabp-branch-2026-09-02-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_tci_co_ltd_biocosme_pabp_branch_2026_09_02_cgmp_2026,
title = {CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to TCI Co., Ltd BioCosme PABP BRANCH, 2026-09-02},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-tci-co-ltd-biocosme-pabp-branch-2026-09-02-cgmp},
note = {Accessed: October 7, 2026}
}